Kaisa Sunela
YOU?
Author Swipe
View article: Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression‐Free Survival in Diffuse Large B‐Cell Lymphoma
Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression‐Free Survival in Diffuse Large B‐Cell Lymphoma Open
Introduction Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease, with often a high Ki‐67 proliferation index. Prognosis is associated with lymphoma stage, lactate dehydrogenase level, and metabolic tumor volume. Thus, intuiti…
View article: Impact of the COVID-19 pandemic on the quality of life of early breast cancer patients undergoing adjuvant chemotherapy – an observational, multicenter study
Impact of the COVID-19 pandemic on the quality of life of early breast cancer patients undergoing adjuvant chemotherapy – an observational, multicenter study Open
Background and purpose: We evaluated the impact of the coronavirus disease 2019 (COVID-19) pandemic on health-related quality of life (HRQoL) in early-stage breast cancer patients receiving adjuvant chemotherapy. Patients and methods: The …
View article: Renal cancer survival and use of 5alpha-reductase inhibitors or androgen deprivation therapy
Renal cancer survival and use of 5alpha-reductase inhibitors or androgen deprivation therapy Open
Purpose Several etiological factors have been implicated in renal cell carcinoma (RCC), and hormonal receptor activity appears to influence RCC-specific mortality. This study aimed to examine the potential association between the use of 5α…
View article: The metabolome of fecal extracellular vesicles in patients with malignant solid tumors
The metabolome of fecal extracellular vesicles in patients with malignant solid tumors Open
View article: mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α)
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α) Open
View article: Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) Open
View article: Biomarker‐adapted treatment in high‐risk large B‐cell lymphoma
Biomarker‐adapted treatment in high‐risk large B‐cell lymphoma Open
Survival rates for patients with high‐risk large B‐cell lymphoma (LBCL), particularly those with biological risk factors, remain inadequate. We conducted a biomarker‐driven phase II trial involving 123 high‐risk patients aged 18–64 with LB…
View article: Defining MRI-based follow-up protocol for primary central nervous system lymphoma
Defining MRI-based follow-up protocol for primary central nervous system lymphoma Open
Background The optimal follow-up protocol for primary central nervous system lymphoma (PCNSL) is unclear. This is the first study to evaluate the benefit of structured follow-up imaging of PCNSL with respect to the timing of relapse. Metho…
View article: Is there a role for structural MRI in PCNSL follow-up?
Is there a role for structural MRI in PCNSL follow-up? Open
Background The optimal follow-up protocol for primary central nervous system lymphoma (PCNSL) is unclear. This is the first study to evaluate the benefit of structured follow-up imaging of PCNSL with respect to the timing of relapse. Metho…
View article: Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study) Open
Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First‐line immunotherapy (IO)‐based combinations have improved the outcome of clear cell RCC patients, including that of…
View article: Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice
Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice Open
Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and…
View article: Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) Open
Background The optimal first-line therapy for metastatic renal cell carcinoma (mRCC) remains uncertain, despite recent advancements in immune-based combinations. This retrospective study compares the effectiveness of pembrolizumab plus axi…
View article: Gut microbiome-derived bacterial extracellular vesicles in patients with solid tumours
Gut microbiome-derived bacterial extracellular vesicles in patients with solid tumours Open
View article: Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria
Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria Open
Mantle cell lymphoma (MCL) is a rare and heterogeneous subgroup of B-cell lymphomas. The clinical course of MCL varies from an indolent form to an extremely aggressive phenotype. MCL is still an incurable disease. However, intensified chem…
View article: Estimating the Lifetime Treatment Burden of Patients With Follicular Lymphoma: A Retrospective Study Using Real-World Multicenter Data
Estimating the Lifetime Treatment Burden of Patients With Follicular Lymphoma: A Retrospective Study Using Real-World Multicenter Data Open
PURPOSE Although follicular lymphoma is characterized by long natural history and frequent relapses, data on the number of patients receiving subsequent therapy lines are scarce. To perform reliable health economical calculations for vario…
View article: Late complications and survival of soft tissue sarcoma patients after adjuvant chemotherapy – a single tertiary centre experience
Late complications and survival of soft tissue sarcoma patients after adjuvant chemotherapy – a single tertiary centre experience Open
View article: Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations Open
No significant differences in terms of patients' outcome seem to clearly emerge, even if the rate CN and the choice of the type of first-line immune-based combination varies across the different Cancer Centers participating in the ARON-1 p…
View article: Rapid diagnosis and initiation of treatment has a crucial role in the prognosis of primary central nervous system lymphoma
Rapid diagnosis and initiation of treatment has a crucial role in the prognosis of primary central nervous system lymphoma Open
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive Non-Hodgkin lymphoma. Diagnosis of PCNSL is challenging and non-specific symptoms can lead to a delay in the diagnosis. After successful therapy, patients have excell…
View article: Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events
Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events Open
View article: LIFETIME TREATMENT BURDEN OF PATIENTS WITH MANTLE CELL LYMPHOMA: SIMULATION‐BASED ANALYSIS OF REAL‐WORLD DATA FROM 20 YEARS
LIFETIME TREATMENT BURDEN OF PATIENTS WITH MANTLE CELL LYMPHOMA: SIMULATION‐BASED ANALYSIS OF REAL‐WORLD DATA FROM 20 YEARS Open
Background: Mantle cell lymphoma (MCL) is a rare subtype of B-cell lymphoma that is currently considered incurable, yet treatable condition with increasing amount of treatment options. Alas, the availability of novel therapies is often lim…
View article: Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020
Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020 Open
Summary Mantle cell lymphoma (MCL) is a rare peripheral B‐cell lymphoma characterised by eventual relapse and progression towards a more aggressive disease biology. With the introduction of rituximab‐ and cytarabine‐based immunochemotherap…
View article: Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma Open
Background Preserving health-related quality of life (HRQOL) is an important goal during renal cell carcinoma treatment. We report HRQOL outcomes from a phase II trial (NCT03173560). Patients and Methods HRQOL data were collected during a …
View article: <scp>FDG‐PET</scp>/<scp>CT</scp>‐guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma
<span>FDG‐PET</span>/<span>CT</span>‐guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma Open
Aim The purpose of the study was to evaluate the clinical impact of fluorodeoxyglucose‐positron emission tomography/computed tomography (FDG‐PET/CT) followed by a new biopsy from the site with maximum standardized uptake value (SUVmax) in …
View article: Mortality among patients with low‐grade follicular lymphoma: A binational retrospective analysis
Mortality among patients with low‐grade follicular lymphoma: A binational retrospective analysis Open
Background The life expectancy of patients with follicular lymphoma (FL) has improved considerably since the introduction of rituximab. This study examined the proportion of deaths from progressive lymphoma and the impact of FL on survival…
View article: Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial Open
View article: FDG‐PET/CT‐GUIDED REBIOPSY MAY FIND CLINICALLY UNSUSPICIOUS TRANSFORMATION OF AN INDOLENT LYMPHOMA AT THE POINT OF DIAGNOSIS OR RELAPSE
FDG‐PET/CT‐GUIDED REBIOPSY MAY FIND CLINICALLY UNSUSPICIOUS TRANSFORMATION OF AN INDOLENT LYMPHOMA AT THE POINT OF DIAGNOSIS OR RELAPSE Open
Introduction: Histologic transformation (HT) to an aggressive lymphoma is a well-described event in the clinical course of indolent lymphomas. When HT occurs, it is common to find both low grade and high grade lymphoma in different areas o…
View article: Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months
Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months Open
Findings regarding the role of sex in follicular lymphoma (FL) are contradictory and the prognostic value of sex among patients with early progression of disease (POD) remains unclear. We collected real-life data from nine hospitals in Fin…
View article: Lymfoomahoitojen jälkeiset pitkäaikaishaitat, niiden ehkäisy ja seuranta
Lymfoomahoitojen jälkeiset pitkäaikaishaitat, niiden ehkäisy ja seuranta Open
Myöhäishaitat ovat edelleen tavallisia lymfoomahoitojen jälkeen, ja niiden riski jatkuu koko elämän. Vaikka hoitojen kehittyminen on vähentänyt haittoja, varsinkin sekundaarisyövät sekä sydän- ja verisuonitaudit aiheuttavat ylikuolleisuutt…
View article: Breast implant-associated anaplastic large cell lymphoma – From diagnosis to treatment
Breast implant-associated anaplastic large cell lymphoma – From diagnosis to treatment Open
View article: Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer
Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer Open